Trial Profile
An Investigation of Levetiracetam in Alzheimer's Disease (ILiAD): a Proof of Concept Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Apr 2023
Price :
$35
*
At a glance
- Drugs Levetiracetam (Primary)
- Indications Alzheimer's disease
- Focus Proof of concept; Therapeutic Use
- Acronyms ILiAD
- 27 Apr 2021 Planned End Date changed from 1 Sep 2021 to 1 Dec 2022.
- 27 Apr 2021 Planned primary completion date changed from 1 Sep 2021 to 1 Dec 2022.
- 25 Mar 2020 Planned End Date changed from 1 Jan 2020 to 1 Sep 2021.